Royalty Pharma Sustainability Profile
Royalty Pharma plc, headquartered in the United States, is a leading player in the biopharmaceutical industry, specialising in the acquisition of revenue-generating pharmaceutical royalties. Founded in 1996, the company has established itself as a pioneer in the royalty financing model, enabling innovation in drug development while providing capital to biopharmaceutical companies. With a diverse portfolio that includes royalties from some of the world's most successful therapies, Royalty Pharma stands out for its unique approach to funding and supporting drug development. The company operates primarily in North America and Europe, positioning itself as a key partner in the life sciences sector. Notable achievements include a robust market presence and a commitment to advancing healthcare through strategic investments in transformative therapies.
DitchCarbon Score
How does Royalty Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Royalty Pharma's score of 35 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Royalty Pharma's reported carbon emissions
In 2024, Royalty Pharma reported approximately 23,266,000 kg CO2e in Scope 3 emissions, specifically from investments. This figure represents a decrease from the previous year's emissions of about 32,002,000 kg CO2e in 2023. The company has consistently disclosed only Scope 3 emissions data, with no reported figures for Scope 1 or Scope 2 emissions in the available years. Over the past few years, Royalty Pharma's Scope 3 emissions from investments have shown a downward trend, with emissions recorded at approximately 19,610,000 kg CO2e in 2022 and about 18,445,000 kg CO2e in 2021. Despite these reductions, the company has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). Royalty Pharma's climate commitments remain vague, with no significant pledges or initiatives reported. The emissions data is sourced directly from Royalty Pharma plc, with no cascading from a parent or related organization. The company continues to focus on transparency in its emissions reporting, although further commitments to climate action would enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | - | - | - | - |
| Scope 3 | 18,445,000 | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Royalty Pharma's Industry?
How Carbon Intensive is Royalty Pharma's Location?
Royalty Pharma's Scope 3 Categories Breakdown
Royalty Pharma's Scope 3 emissions, which decreased by 27% last year and increased by approximately 26% since 2021, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Investments" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Royalty Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Royalty Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.